Repros Therapeutics Company Profile (NASDAQ:RPRX)

Analyst Ratings

Consensus Ratings for Repros Therapeutics (NASDAQ:RPRX) (?)
Ratings Breakdown: 1 Sell Rating(s), 3 Hold Rating(s), 1 Buy Rating(s)
Consensus Rating:Hold (Score: 2.00)
Consensus Price Target: $23.67 (1,284.02% upside)

Analysts' Ratings History for Repros Therapeutics (NASDAQ:RPRX)
Show:
DateFirmActionRatingPrice TargetActions
2/9/2016Piper Jaffray Cos.Reiterated RatingNeutralView Rating Details  Tweet This Rating  Share This Rating on StockTwits
12/4/2015Brean CapitalReiterated RatingHoldView Rating Details  Tweet This Rating  Share This Rating on StockTwits
10/30/2015Ladenburg ThalmannDowngradeBuy -> NeutralView Rating Details  Tweet This Rating  Share This Rating on StockTwits
10/30/2015Bank of America Corp.DowngradeNeutral -> UnderperformView Rating Details  Tweet This Rating  Share This Rating on StockTwits
7/28/2015LaidlawReiterated RatingBuy$28.00View Rating Details  Tweet This Rating  Share This Rating on StockTwits
8/29/2014Ascendiant Capital MarketsReiterated RatingPositiveView Rating Details  Tweet This Rating  Share This Rating on StockTwits
(Data available from 7/27/2014 forward)

Earnings

Earnings History for Repros Therapeutics (NASDAQ:RPRX)
DateQuarterConsensus EstimateActual EPSRevenue EstimateActual RevenueRelease LinkConference CallActions
8/8/2016        
5/10/2016Q1($0.22)($0.20)ViewN/AView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
3/14/2016Q4($0.27)($0.26)ViewN/AView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
11/9/2015Q3($0.29)($0.27)ViewN/AView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
8/10/2015Q2($0.26)($0.32)ViewN/AView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
3/16/2015Q414($0.34)($0.31)ViewN/AView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
11/10/2014Q314($0.39)($0.32)ViewN/AView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
8/11/2014($0.37)($0.38)ViewN/AView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
5/12/2014Q114($0.35)($0.37)ViewN/AView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
3/13/2014Q413($0.29)($0.31)ViewN/AView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
8/7/2013Q213($0.40)($0.38)ViewN/AView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
5/10/2013Q1 2013($0.35)($0.41)ViewN/AView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
3/18/2013Q412($0.28)($0.47)$0.00 million$0.00 millionViewN/AView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
11/13/2012Q312($0.24)($0.30)ViewN/AView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
(Data available from 1/1/2011 forward)

Estimates

Earnings Estimates for Repros Therapeutics (NASDAQ:RPRX)
No earnings estimates for this company have been tracked by MarketBeat.com

Dividends

Dividend History for Repros Therapeutics (NASDAQ:RPRX)
No dividend announcements for this company have been tracked by MarketBeat.com

Insider Trades

Insider Trading History for Repros Therapeutics (NASDAQ:RPRX)
Transaction DateInsider NameTitleBuy/SellNumber of SharesAverage Share PriceTotal TransactionActions
2/18/2016Joseph PodolskiCEOBuy10,000$0.93$9,300.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
1/7/2016Joseph PodolskiCEOBuy11,677$1.18$13,778.86View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
11/12/2014Joseph PodolskiCEOBuy4,700$9.42$44,274.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
11/12/2014Katherine AndersonCFOBuy3,500$9.41$32,935.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
8/14/2014Joseph PodolskiCEOBuy2,100$13.91$29,211.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
8/14/2014Katherine AndersonCFOBuy2,000$13.85$27,700.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
10/25/2013Joseph PodolskiCEOBuy3,000$18.03$54,090.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
10/25/2013Katherine AndersonCFOBuy1,000$17.90$17,900.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
10/10/2013Katherine AndersonCFOBuy1,000$23.77$23,770.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
2/1/2013Katherine AndersonCFOBuy1,000$11.89$11,890.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
(Data available from 1/1/2013 forward)

Headlines

Latest Headlines for Repros Therapeutics (NASDAQ:RPRX)
DateHeadline
07/27/16 09:15 AMRepros Therapeutics Inc. (RPRX) Drops 5.08% on July 25 - Equities.com
07/21/16 06:31 PMChecking in on Stock Volatility for: Repros Therapeutics Inc. (NASDAQ:RPRX) - Engelwood Daily
07/21/16 06:31 PMPerformance watch list: Repros Therapeutics Inc. (NASDAQ:RPRX) - News Oracle
07/20/16 07:04 PMStock Bending Down in Today's Session: Repros Therapeutics Inc. (NASDAQ:RPRX) - TGP
07/20/16 07:04 PMNews review of 2 biotech stocks: Repros Therapeutics (RPRX), Eleven Biotherapeutics (EBIO) - The Voice Registrar
07/20/16 07:04 PMRepros Therapeutics Inc. (RPRX) Jumps 16.57% on July 19 - Equities.com
07/18/16 11:43 AMStrong Sell Calls For Repros Therapeutics Inc. (NASDAQ:RPRX) At 0 - Investor Newswire
07/17/16 10:17 AMShares Moving Down on the Week: Repros Therapeutics Inc. (NASDAQ:RPRX) - Engelwood Daily
07/16/16 09:26 AMBiogen Inc. (NASDAQ:BIIB) Increased 0.67%: Repros Therapeutics Inc. (NASDAQ:RPRX), Bristol-Myers Squibb ... - KC Register
07/16/16 09:26 AMAnalyst Target and Average Rating Watch: Repros Therapeutics Inc. (NASDAQ:RPRX) - Press Telegraph
07/13/16 09:05 AMRepros Therapeutics Incorporated (NASDAQ:RPRX) Shorts Decreased by 16.84% After Short Covering - Consumer Eagle
07/13/16 09:05 AMRepros Therapeutics Inc. (NASDAQ:RPRX) Wall Street Analyst Recommendation Outlook - Telanagana Press
07/09/16 09:16 AMBrokers Issue Average Price Target Of 10.67 On Repros Therapeutics Inc. (RPRX) - Fiscal Standard
07/08/16 06:09 PMHeightened Volatility Check on: Repros Therapeutics Inc. (NASDAQ:RPRX) - Engelwood Daily
07/08/16 06:09 PMCan Repros Therapeutics Inc. (NASDAQ:RPRX) Improve on the Earnings Front? - Engelwood Daily
07/08/16 06:09 PMCompany Stock Focus for Repros Therapeutics Inc. (NASDAQ:RPRX): Which Way Will Shares Head? - Press Telegraph
07/08/16 06:09 PM2016 Q1 Sentiment Repros Therapeutics Inc (NASDAQ:RPRX) - Engelwood Daily
07/06/16 10:51 AMRepros Therapeutics Inc. (NASDAQ:RPRX) Stock Update: Check on Ratings and Target Price - Telanagana Press
07/05/16 10:37 AMRepros Therapeutics Inc. (NASDAQ:RPRX) Expected to Reach Highs Of $2 - Investor Newswire
07/05/16 10:37 AMBroker Outlook For The Week Ahead Repros Therapeutics Inc. (RPRX) - Fiscal Standard
07/02/16 08:53 AMRepros Therapeutics Incorporated (NASDAQ:RPRX) Sellers Covered 16.84% of Their Shorts - Press Telegraph
06/30/16 06:27 PMAre Analysts Bullish Repros Therapeutics Inc (NASDAQ:RPRX) After Last Week? - Engelwood Daily
06/30/16 09:01 AMNew Broker Ratings For Repros Therapeutics Inc. (RPRX) - FTSE News
06/30/16 09:01 AMRepros Therapeutics Inc. (NASDAQ:RPRX) Company Rating and Target Watch - Telanagana Press
06/30/16 09:01 AMRepros Therapeutics Inc. (RPRX) Jumps 5.44% on June 28 - Equities.com
06/28/16 06:06 PMCheck on Share Volatility: Repros Therapeutics Inc. (NASDAQ:RPRX) - Engelwood Daily
06/28/16 06:06 PMRepros Therapeutics Incorporated (NASDAQ:RPRX) Short Interest Decreased By 16.84% - Engelwood Daily
06/27/16 10:20 AMShare Update and Earnings Review for Repros Therapeutics Inc. (NASDAQ:RPRX) - Press Telegraph
06/27/16 10:20 AMNext Weeks Broker Price Targets For Repros Therapeutics Inc. (RPRX) - Fiscal Standard
06/26/16 05:12 PMStrong Sell Calls Recommendations For Repros Therapeutics Inc. (NASDAQ:RPRX) At 0 - Investor Newswire
06/26/16 10:37 AMShare Volatility Check for: Repros Therapeutics Inc. (NASDAQ:RPRX) - Press Telegraph
06/24/16 08:46 AMWere Analysts Bullish Repros Therapeutics Inc (NASDAQ:RPRX) This Week? - Press Telegraph
06/24/16 08:46 AMCovering the Bases on Repros Therapeutics Inc. (NASDAQ:RPRX): Where is the Stock Going? - Press Telegraph
06/24/16 08:46 AMRepros Therapeutics Inc. (NASDAQ:RPRX) Earnings Glance and Target Price Review - Engelwood Daily
06/24/16 07:54 AMResearch Report Initiated on Select Biotechnology Equities -
06/20/16 07:44 AMStrong Buy Calls Count For Repros Therapeutics Inc. (NASDAQ:RPRX) At 0 - Investor Newswire
06/14/16 05:54 PMTrend Of Rating Given To Repros Therapeutics Inc. (NASDAQ:RPRX) - Investor Newswire
06/11/16 09:05 AMRepros Therapeutics Inc. (RPRX) Drops 5.32% on June 09 - Equities.com
06/10/16 06:32 PMRepros Therapeutics Inc. (RPRX) Updated Price Targets - FTSE News
06/10/16 09:12 AMRepros Therapeutics Inc. (RPRX) Drops 5.05% on June 08 - Equities.com
06/07/16 12:44 PMREPROS THERAPEUTICS INC. Files SEC form 8-K, Regulation FD Disclosure -
06/04/16 06:13 PMAnalyst Earnings Report: SINA Corporation (NASDAQ:SINA), Repros Therapeutics Inc. (NASDAQ:RPRX) - Beacon Chronicle
06/03/16 06:48 PMStocks Earnings Report: Repros Therapeutics Inc. (NASDAQ:RPRX), PayPal Holdings, Inc. (NASDAQ:PYPL) - Beacon Chronicle
06/03/16 06:48 PMHC Stocks Broker Alerts: Repros Therapeutics Inc (NASDAQ:RPRX), Synergy Pharmaceuticals Inc (NASDAQ:SGYP) - share market updates (press release)
06/03/16 09:07 AMShare Rating Focus on Repros Therapeutics Inc. (NASDAQ:RPRX) - HNN
06/03/16 09:07 AMAnalyst's Valuable Buzzers: Pfizer, Inc. (NYSE:PFE) , Repros Therapeutics Inc. (NASDAQ:RPRX) - Street Updates
06/02/16 06:39 PMStocks for Your Portfolio: Repros Therapeutics Inc (NASDAQ:RPRX), Medovex Corp. (NASDAQ:MDVX), Macrocure Ltd ... - The Point Review - The Point ReviewStocks for Your Portfolio: Repros Therapeutics Inc (NASDAQ:RPRX), Medovex Corp. (NASDAQ:MDVX), Macrocure Ltd ...The Point ReviewShares of Repros Therapeutics Inc (NASDAQ:RPRX) flew 22.19% to $2.07 at 12:14 PM EDT. The stock attained the volume of 3.66 Million shares recently versus average trading volume of 1.04 Million shares. If we take a look on its volatility, 7.50 percent ...and more »
06/02/16 06:39 PMThursday's Morning Insights: Repros Therapeutics Inc (RPRX), Keryx Biopharmaceuticals (KERX), and Conn's Inc ... - Smarter Analyst - Thursday's Morning Insights: Repros Therapeutics Inc (RPRX), Keryx Biopharmaceuticals (KERX), and Conn's Inc ...Smarter AnalystRepros Therapeutics Inc (NASDAQ:RPRX) is soaring nearly 19% this morning to $2.01 following yesterday's positive news that provided an update on the company's EU submission for enclomiphene. The company explained that the marketing authorization ...and more »
06/02/16 09:17 AMTarget Price and Stock Performance Rundown for Repros Therapeutics Inc. (NASDAQ:RPRX) - HNN - Target Price and Stock Performance Rundown for Repros Therapeutics Inc. (NASDAQ:RPRX)HNNDuring the latest trading session, Repros Therapeutics Inc. (NASDAQ:RPRX) shares traded -8.65%. Monitoring the stock price relative to moving averages may offer enhanced perspective on stock performance. After a recent check, shares have been seen ...and more »
06/02/16 09:17 AMTop 10 Pre-Market Gainers From Thursday - Benzinga - Top 10 Pre-Market Gainers From ThursdayBenzingaRepros Therapeutics RPRX 25.44% was trading up 19.53% after reporting success of its Enclomiphene drug to treat secondary hypogonadism. The Drug is on track for ... Joy Global Inc. JOY 9.94% traded up 9.65% after beating EPS estimates. Donaldson ...

Social

About Repros Therapeutics

Repros Therapeutics logoRepros Therapeutics, Inc. is a biopharmaceutical company focused on the development of new drugs to treat hormonal and reproductive system disorders. The Company's product candidates include Androxal and Proellex. The Company's primary product candidate Androxal is a single isomer of clomiphene citrate and an orally active proprietary small molecule compound, which is developed for the treatment of secondary hypogonadism in overweight men. The Company's Proellex product candidate for female reproductive health is a chemical entity that acts as a selective blocker of the progesterone receptor and is being developed for the treatment of symptoms associated with uterine fibroids and endometriosis.

Industry, Sector and Symbol:
  • Sector: Medical
  • Industry: Biotechnology
  • Sub-Industry: Pharmaceuticals
  • Exchange: NASDAQ
  • Symbol: RPRX
  • CUSIP: 76028H20
Key Metrics:
  • Previous Close: $1.71
  • 50 Day Moving Average: $1.70
  • 200 Day Moving Average: $1.50
  • P/E Ratio: N/A
  • P/E Growth: -0.08
  • Market Cap: $42.31M
  • Beta: -0.29
  • Current Year EPS Consensus Estimate: $-0.74 EPS
Additional Links:
Repros Therapeutics (NASDAQ:RPRX) Chart for Wednesday, July, 27, 2016